Deviations from written production and process control procedures are not recorded and justified.
Inspection Record
Octapharma AB — FDA 483 Findings
Inspectors Alan L Truong · Ze Peng · Olga Simakova and 1 moreThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Written procedures are not established and followed that describe the in-process controls to be conducted on appropriate samples of in-process materials of each batch.
Equipment and(b) (4) are not maintained at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drug product.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.